Mabwell Bioscience, Insilico Medicine, and ChemExpress forging ahead with ADC innovation through strategic collaboration

CAR-T Digest - August 2020

22 September 2025: Mabwell Bioscience, Insilico Medicine, and ChemExpress forging ahead with ADC innovation through strategic collaboration

Mabwell Bioscience, Insilico Medicine, and ChemExpress formed a strategic collaboration to jointly develop a novel ADC compound library, advance next-generation ADC candidates, and accelerate industrialization of innovative ADCs
Mabwell contributes its proprietary ADC platform, extensive antibody resources, and strong clinical development expertise across oncology and autoimmune diseases
Insilico leverages its AI-powered Pharma.AI platform to design novel payload-linkers with high selectivity, applying expertise validated in the development of Rentosertib, the first AI-designed drug
ChemExpress provides expertise in linker-payload synthesis, molecular building blocks, and end-to-end CRO/CDMO services supporting discovery through commercialization
The partnership pioneers an “ABC” model (AI + Biotech/Biopharma + CRO/CDMO), creating a closed-loop ADC development system that shortens optimization timelines, enhances R&D efficiency, and aims to deliver safer, more effective ADC therapies worldwide